PCM
NBIX icon

Penn Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Penn Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,271
Closed -$391K – 182
2022
Q4 		$391K Sell
3,271
-85
-3% -$9.96K 0.04% 151
2022
Q3 		$356K Sell
3,356
-154
-4% -$15.6K 0.04% 162
2022
Q2 		$342K Sell
3,510
-57
-2% -$5.26K 0.04% 178
2022
Q1 		$334K Buy
3,567
+691
+24% +$58.6K 0.03% 184
2021
Q4 		$245K Buy
2,876
+10
+0.3% +$920 0.02% 201
2021
Q3 		$275K Sell
2,866
-149
-5% -$14.1K 0.03% 192
2021
Q2 		$293K Sell
3,015
-28
-0.9% -$2.68K 0.03% 204
2021
Q1 		$296K Sell
3,043
-11
-0.4% -$1.15K 0.03% 199
2020
Q4 		$293K Sell
3,054
-19,401
-86% -$1.87M 0.04% 189
2020
Q3 		$2.22M Buy
22,455
+8,062
+56% +$933K 0.28% 138
2020
Q2 		$1.8M Buy
+14,393
New +$1.59M 0.23% 152

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Penn Capital Management's NBIX Position: Q1 2023 in Review

Penn Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 3,271 shares — an estimated $391K sold.

Penn Capital Management first reported a position in NBIX in Q2 2020 and held it in 11 quarters. The position peaked at $2.22M in Q3 2020. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • Penn Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • Penn Capital Management sold 3,271 Neurocrine Biosciences shares in Q1 2023, an estimated $391K.
  • Penn Capital Management first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 11 quarters.
  • Penn Capital Management's Neurocrine Biosciences position peaked at $2.22M in Q3 2020.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Penn Capital Management's 13F filing for Q1 2023, filed 12 May 2023.